Publication of ACIP statements in the CX-5461 supplier MMWR is the final step providing them status as official recommendations of the US Government. The estimated annual running costs of operating the committee, including compensation and travel expenses for members but excluding staff support,

was US$122,138 in 2008. The estimated annual number of person-years of staff support required is 3.9, at an estimated annual cost of US$477,068. The scope of the ACIP’s work focuses on development of national policy for the use of vaccines and other biologics and antimicrobials targeting vaccine-preventable diseases. The committee votes on whether to include a new vaccine in the routine immunization schedule, vaccine use in high risk groups, and use of vaccines outside the routine schedules (e.g. rabies, Japanese encephalitis). ACIP also makes recommendations on vaccine formulations (e.g., multivalent vs. monovalent NLG919 presentations) as well as recommendations on different vaccines targeting the same disease (e.g., rotavirus and human papillomavirus vaccines). ACIP may recommend that additional studies be conducted to aid decision making (e.g., to provide

local disease burden or cost-effectiveness analyses) when necessary. For each recommended vaccine, the committee develops written guidance, subject to the approval of the CDC Director, for administration of FDA-licensed vaccines to children and adults in the US civilian population, including age for vaccine administration, dose and frequency of administration, and precautions and contraindications of vaccine use and information on adverse events. In addition, as provided by Section 1928

of the Social Security Act, the ACIP designates those vaccines to be included in the Vaccines for Children (VFC) Program.1 Apart from the VFC Program, reimbursement for vaccine administration is usually covered by private insurance companies. Although ACIP Farnesyltransferase recommendations do not carry any legal mandate, they are generally regarded as national policy and are respected and adopted by most private insurers; the inclusion on ACIP of a liaison representative from America’s Health Insurance Plans (AHIP) facilitates communications with private insurers. The committee may alter or withdraw its recommendation(s) regarding a particular vaccine when new information becomes available or the risk of disease changes. A recent initiative has been undertaken by the ACIP Secretariat to ensure that every ACIP Recommendation is reviewed every 3–5 years and revised, renewed, or retired as needed. As new vaccines are licensed and subsequently recommended by the ACIP, they are incorporated into the childhood and adult immunization schedules [4] and [5].